JP6411360B2 - 治療タンパク質の精製方法 - Google Patents

治療タンパク質の精製方法 Download PDF

Info

Publication number
JP6411360B2
JP6411360B2 JP2015545601A JP2015545601A JP6411360B2 JP 6411360 B2 JP6411360 B2 JP 6411360B2 JP 2015545601 A JP2015545601 A JP 2015545601A JP 2015545601 A JP2015545601 A JP 2015545601A JP 6411360 B2 JP6411360 B2 JP 6411360B2
Authority
JP
Japan
Prior art keywords
fibrinogen
solution
vwf
resin
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015545601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501878A (ja
JP2016501878A5 (https=
Inventor
ハン・ファム
ジェフリー・マイケル・ヘイ
ダレン・ングイ
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JP2016501878A publication Critical patent/JP2016501878A/ja
Publication of JP2016501878A5 publication Critical patent/JP2016501878A5/ja
Application granted granted Critical
Publication of JP6411360B2 publication Critical patent/JP6411360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2015545601A 2012-12-05 2013-12-05 治療タンパク質の精製方法 Active JP6411360B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261733761P 2012-12-05 2012-12-05
US61/733,761 2012-12-05
EP13153898.5 2013-02-04
EP13153898 2013-02-04
US13/803,740 US20140154233A1 (en) 2012-12-05 2013-03-14 Method of purifying therapeutic proteins
US13/803,740 2013-03-14
AU2013203357A AU2013203357B2 (en) 2012-12-05 2013-04-10 A method of purifying therapeutic proteins
AU2013203357 2013-04-10
PCT/AU2013/001414 WO2014085861A1 (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018178301A Division JP6836562B2 (ja) 2012-12-05 2018-09-25 治療タンパク質の精製方法

Publications (3)

Publication Number Publication Date
JP2016501878A JP2016501878A (ja) 2016-01-21
JP2016501878A5 JP2016501878A5 (https=) 2017-01-19
JP6411360B2 true JP6411360B2 (ja) 2018-10-24

Family

ID=47630209

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015545601A Active JP6411360B2 (ja) 2012-12-05 2013-12-05 治療タンパク質の精製方法
JP2018178301A Active JP6836562B2 (ja) 2012-12-05 2018-09-25 治療タンパク質の精製方法
JP2021016182A Active JP7774384B2 (ja) 2012-12-05 2021-02-04 治療タンパク質の精製方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018178301A Active JP6836562B2 (ja) 2012-12-05 2018-09-25 治療タンパク質の精製方法
JP2021016182A Active JP7774384B2 (ja) 2012-12-05 2021-02-04 治療タンパク質の精製方法

Country Status (12)

Country Link
US (5) US20140154233A1 (https=)
EP (2) EP3483173A1 (https=)
JP (3) JP6411360B2 (https=)
KR (2) KR102240978B1 (https=)
CN (2) CN109125714B (https=)
AU (2) AU2013203357B2 (https=)
BR (1) BR112015012854B1 (https=)
CA (2) CA2893373A1 (https=)
PL (1) PL2928905T3 (https=)
RU (1) RU2685956C2 (https=)
SG (2) SG10201704484QA (https=)
WO (1) WO2014085861A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351340B (es) 2012-03-13 2017-10-11 Octapharma Ag Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este.
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
AU2017205364B2 (en) * 2016-01-07 2021-03-04 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions
EP4293116A3 (fr) 2016-07-06 2024-01-24 Laboratoire Français du Fractionnement et des Biotechnologies Fibrinogène liquide stable
CA3035650A1 (en) * 2016-09-01 2018-03-08 Plas-Free Ltd Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
KR20200038309A (ko) * 2017-08-23 2020-04-10 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법
ES2983341T3 (es) * 2018-02-28 2024-10-22 Plas Free Ltd Dispositivo extracorpóreo y matriz para la eliminación de proteínas fibrinolíticas de fluidos biológicos, métodos y usos de los mismos
CN109078628B (zh) * 2018-08-27 2021-06-11 西北大学 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
US12173307B2 (en) * 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
WO2022218962A1 (en) 2021-04-13 2022-10-20 Grifols Worldwide Operations Limited Liquid composition comprising factor viii or factor viii/von willebrand factor complex
CN115181178B (zh) * 2021-09-04 2024-04-26 广东双林生物制药有限公司 一种从冷沉淀中制备人纤维蛋白原的方法
EP4456935A1 (en) 2021-12-30 2024-11-06 Baxter International Inc. Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
ATE180492T1 (de) * 1991-09-05 1999-06-15 Baxter Int Topischer fibrinogenkomplex
FR2686883B1 (fr) * 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
ES2139227T5 (es) 1994-07-14 2011-05-04 Caf-Dcf Département Central De Fractionnement De La Croix Rouge S.C.R.L. Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación.
CA2198928A1 (en) * 1994-09-02 1996-03-14 Samar Nath Roy Production and secretion of recombinant fibrinogen by yeast
US6037457A (en) * 1997-01-31 2000-03-14 The University Of North Carolina At Chapel Hill Method for recombinant fibrinogen production
FR2772381B1 (fr) 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
ATE328007T1 (de) * 1998-09-24 2006-06-15 Pharming Intellectual Pty Bv Reinigung von fibrinogen aus flüssigkeiten mittels ausfällung und hydrophobischer- interaktion-chromatographie
WO2001048016A1 (en) 1999-12-23 2001-07-05 Csl Limited Separation of fibrinogen from plasma proteases
WO2001046016A1 (en) 1999-12-23 2001-06-28 Rast Rodger H System and method for providing individualized dosing
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
SK288005B6 (sk) * 2001-05-21 2012-10-02 Omrix Biopharmaceuticals S. A. In vitro method for specifically removing or isolating plasminogen or plasmin and support used in this method
AUPR638801A0 (en) 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
WO2003028743A1 (en) * 2001-10-03 2003-04-10 Woolverton Christopher J Storage-stable fibrinogen solutions
AU2002340776A1 (en) * 2001-10-30 2003-05-12 Novozymes A/S High throughput isolation of proteins by charge induction chromatography
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
CA2478925C (en) 2002-04-26 2016-06-07 Robert Lee Fahrner Non-affinity purification of proteins
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DE10246125A1 (de) 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
ES2214967B1 (es) 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
DE102004009400A1 (de) * 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
CA2583081A1 (en) * 2004-06-16 2006-01-19 Bio-Rad Laboratories, Inc. Multichemistry fractionation
DK2102335T3 (da) * 2007-01-04 2012-05-07 Crucell Holland Bv Rensning af faktor XI
US8399620B2 (en) 2007-07-11 2013-03-19 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
EP2027875A1 (en) 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
WO2009090056A2 (en) 2008-01-18 2009-07-23 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
KR20160104740A (ko) * 2008-06-24 2016-09-05 옥타파마 아게 응고 인자 ｖｉｉｉ을 정제하는 방법
DK2521566T3 (en) * 2010-01-08 2014-12-08 Profibrix Bv Fibrinogen preparations enriched with fibrinogen with an extended alpha chain
WO2012038410A1 (en) 2010-09-20 2012-03-29 Octapharma Ag Process for production of fibrinogen
CN103429609A (zh) * 2010-12-08 2013-12-04 安姆根有限公司 在氨基酸存在下的离子交换层析
MX351340B (es) 2012-03-13 2017-10-11 Octapharma Ag Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este.
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins

Also Published As

Publication number Publication date
KR20150090252A (ko) 2015-08-05
CA2893373A1 (en) 2014-06-12
AU2013354899A1 (en) 2015-07-16
RU2685956C2 (ru) 2019-04-23
EP3483173A1 (en) 2019-05-15
PL2928905T3 (pl) 2019-05-31
BR112015012854B1 (pt) 2021-11-30
BR112015012854A2 (pt) 2017-07-11
JP7774384B2 (ja) 2025-11-21
KR102403847B1 (ko) 2022-05-31
JP6836562B2 (ja) 2021-03-03
US20140154233A1 (en) 2014-06-05
RU2015126551A (ru) 2017-01-10
AU2013203357B2 (en) 2015-08-27
EP2928905A4 (en) 2016-06-08
KR20210042422A (ko) 2021-04-19
SG10201704484QA (en) 2017-07-28
WO2014085861A1 (en) 2014-06-12
KR102240978B1 (ko) 2021-04-19
US11426680B2 (en) 2022-08-30
US20210283530A1 (en) 2021-09-16
JP2016501878A (ja) 2016-01-21
CN104981476B (zh) 2018-10-09
US20190209948A1 (en) 2019-07-11
US20170143805A1 (en) 2017-05-25
EP2928905B1 (en) 2018-11-21
JP2019011346A (ja) 2019-01-24
AU2013354899B2 (en) 2018-05-17
CN109125714A (zh) 2019-01-04
CN104981476A (zh) 2015-10-14
AU2013203357A1 (en) 2014-06-19
HK1214833A1 (en) 2016-08-05
US20150158906A1 (en) 2015-06-11
SG11201504372UA (en) 2015-07-30
EP2928905A1 (en) 2015-10-14
CN109125714B (zh) 2022-08-02
JP2021073280A (ja) 2021-05-13
US9598461B2 (en) 2017-03-21
CA3185085A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
JP7774384B2 (ja) 治療タンパク質の精製方法
AU2003244850B2 (en) Processes for the preparation of fibrinogen
US10188965B2 (en) Hydrophobic charge induction chromatographic depletion of a protein from a solution
HK40007788A (en) Separation of fibrinogen, fviii and/or vwf from plasma proteases by hcic
ES2711455T3 (es) Un método de purificación de proteínas terapéuticas
HK1214833B (en) A method of purifying therapeutic proteins
RU2559576C1 (ru) Способ получения вирусбезопасного полного протромбинового комплекса

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180926

R150 Certificate of patent or registration of utility model

Ref document number: 6411360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250